MiMedx (MDXG)
Market Price (2/19/2026): $5.18 | Market Cap: $766.8 MilSector: Health Care | Industry: Biotechnology
MiMedx (MDXG)
Market Price (2/19/2026): $5.18Market Cap: $766.8 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 5.3%, FCF Yield is 8.2% | Weak multi-year price returns2Y Excs Rtn is -73%, 3Y Excs Rtn is -49% | Key risksMDXG key risks include [1] its history of financial fraud allegations, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -16% | ||
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 17%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 16% | ||
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -31% | ||
| Low stock price volatilityVol 12M is 40% | ||
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more. |
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 5.3%, FCF Yield is 8.2% |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -16% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 17%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 16% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -31% |
| Low stock price volatilityVol 12M is 40% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -73%, 3Y Excs Rtn is -49% |
| Key risksMDXG key risks include [1] its history of financial fraud allegations, Show more. |
Qualitative Assessment
AI Analysis | Feedback
MiMedx (MDXG) stock has lost about 30% since 10/31/2025 because of the following key factors:
1. Medicare Reimbursement Policy Changes Effective January 2026.MiMedx's stock movement has been significantly impacted by new Medicare reimbursement policies that took effect on January 1, 2026. The Centers for Medicare and Medicaid Services (CMS) introduced the "Wasteful and Inappropriate Service Reduction (Wiser) model," which includes skin substitutes, and proposed changes to the physician fee schedule and Outpatient Prospective Payment System for calendar year 2026. These changes shift away from the previous Average Sales Price (ASP) methodology towards a fixed payment for skin substitutes, leading to expectations of near-term average selling price (ASP) compression for MiMedx's products. Analysts have connected the stock's decline to these industry pressures, as payers are demanding stronger cost-benefit evidence for high-cost biologics.
2. Analyst Downgrades and Price Target Reductions.Throughout the period, MiMedx experienced several negative adjustments from financial analysts. Mizuho notably cut its price target for MiMedx Group from $12.00 to $10.00 in mid-December 2025. Further, in late January 2026, StockInvest.us downgraded the company's stock to a "Strong Sell Candidate." Additionally, Northland Securities lowered its earnings per share (EPS) estimates for fiscal year 2027 in January 2026, contributing to a more pessimistic outlook for the company's future financial performance.
Show more
1. Medicare Reimbursement Policy Changes Effective January 2026.MiMedx's stock movement has been significantly impacted by new Medicare reimbursement policies that took effect on January 1, 2026. The Centers for Medicare and Medicaid Services (CMS) introduced the "Wasteful and Inappropriate Service Reduction (Wiser) model," which includes skin substitutes, and proposed changes to the physician fee schedule and Outpatient Prospective Payment System for calendar year 2026. These changes shift away from the previous Average Sales Price (ASP) methodology towards a fixed payment for skin substitutes, leading to expectations of near-term average selling price (ASP) compression for MiMedx's products. Analysts have connected the stock's decline to these industry pressures, as payers are demanding stronger cost-benefit evidence for high-cost biologics.
2. Analyst Downgrades and Price Target Reductions.Throughout the period, MiMedx experienced several negative adjustments from financial analysts. Mizuho notably cut its price target for MiMedx Group from $12.00 to $10.00 in mid-December 2025. Further, in late January 2026, StockInvest.us downgraded the company's stock to a "Strong Sell Candidate." Additionally, Northland Securities lowered its earnings per share (EPS) estimates for fiscal year 2027 in January 2026, contributing to a more pessimistic outlook for the company's future financial performance.
Show more
Stock Movement Drivers
Fundamental Drivers
The -31.8% change in MDXG stock from 10/31/2025 to 2/18/2026 was primarily driven by a -31.8% change in the company's P/E Multiple.| (LTM values as of) | 10312025 | 2182026 | Change |
|---|---|---|---|
| Stock Price ($) | 7.65 | 5.22 | -31.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 393 | 393 | 0.0% |
| Net Income Margin (%) | 10.4% | 10.4% | 0.0% |
| P/E Multiple | 27.7 | 18.9 | -31.8% |
| Shares Outstanding (Mil) | 148 | 148 | 0.0% |
| Cumulative Contribution | -31.8% |
Market Drivers
10/31/2025 to 2/18/2026| Return | Correlation | |
|---|---|---|
| MDXG | -31.8% | |
| Market (SPY) | 0.6% | 31.9% |
| Sector (XLV) | 9.3% | 24.1% |
Fundamental Drivers
The -27.4% change in MDXG stock from 7/31/2025 to 2/18/2026 was primarily driven by a -42.7% change in the company's P/E Multiple.| (LTM values as of) | 7312025 | 2182026 | Change |
|---|---|---|---|
| Stock Price ($) | 7.19 | 5.22 | -27.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 364 | 393 | 8.2% |
| Net Income Margin (%) | 8.8% | 10.4% | 17.3% |
| P/E Multiple | 33.0 | 18.9 | -42.7% |
| Shares Outstanding (Mil) | 148 | 148 | -0.2% |
| Cumulative Contribution | -27.4% |
Market Drivers
7/31/2025 to 2/18/2026| Return | Correlation | |
|---|---|---|
| MDXG | -27.4% | |
| Market (SPY) | 8.9% | 33.9% |
| Sector (XLV) | 21.4% | 23.1% |
Fundamental Drivers
The -40.0% change in MDXG stock from 1/31/2025 to 2/18/2026 was primarily driven by a -59.8% change in the company's Net Income Margin (%).| (LTM values as of) | 1312025 | 2182026 | Change |
|---|---|---|---|
| Stock Price ($) | 8.70 | 5.22 | -40.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 343 | 393 | 14.8% |
| Net Income Margin (%) | 25.8% | 10.4% | -59.8% |
| P/E Multiple | 14.5 | 18.9 | 31.0% |
| Shares Outstanding (Mil) | 147 | 148 | -0.7% |
| Cumulative Contribution | -40.0% |
Market Drivers
1/31/2025 to 2/18/2026| Return | Correlation | |
|---|---|---|
| MDXG | -40.0% | |
| Market (SPY) | 15.0% | 35.4% |
| Sector (XLV) | 8.8% | 30.4% |
Fundamental Drivers
The 34.9% change in MDXG stock from 1/31/2023 to 2/18/2026 was primarily driven by a 61.1% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 1312023 | 2182026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.87 | 5.22 | 34.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 244 | 393 | 61.1% |
| P/S Multiple | 1.8 | 2.0 | 9.3% |
| Shares Outstanding (Mil) | 113 | 148 | -23.4% |
| Cumulative Contribution | 34.9% |
Market Drivers
1/31/2023 to 2/18/2026| Return | Correlation | |
|---|---|---|
| MDXG | 34.9% | |
| Market (SPY) | 75.1% | 23.7% |
| Sector (XLV) | 23.7% | 18.3% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| MDXG Return | -33% | -54% | 215% | 10% | -30% | -24% | -43% |
| Peers Return | 16% | -32% | 22% | 1% | -5% | -7% | -14% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -0% | 82% |
Monthly Win Rates [3] | |||||||
| MDXG Win Rate | 67% | 33% | 67% | 50% | 17% | 50% | |
| Peers Win Rate | 56% | 40% | 58% | 48% | 48% | 38% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| MDXG Max Drawdown | -39% | -56% | 0% | -37% | -40% | -27% | |
| Peers Max Drawdown | -4% | -49% | -20% | -29% | -30% | -12% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: ORGO, IART, SYK, VCEL.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 2/18/2026 (YTD)
How Low Can It Go
| Event | MDXG | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -83.4% | -25.4% |
| % Gain to Breakeven | 501.9% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -58.2% | -33.9% |
| % Gain to Breakeven | 139.1% | 51.3% |
| Time to Breakeven | 267 days | 148 days |
| 2018 Correction | ||
| % Loss | -86.6% | -19.8% |
| % Gain to Breakeven | 645.2% | 24.7% |
| Time to Breakeven | Not Fully Recovered days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -92.2% | -56.8% |
| % Gain to Breakeven | 1175.0% | 131.3% |
| Time to Breakeven | 1,444 days | 1,480 days |
Compare to ORGO, IART, SYK, VCEL
In The Past
MiMedx's stock fell -83.4% during the 2022 Inflation Shock from a high on 9/8/2021. A -83.4% loss requires a 501.9% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About MiMedx (MDXG)
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a semi-permeable protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications; and AMNIOBURN a semi-permeable protective barrier allograft used in the treatment of partial-thickness and full-thickness burns, as well as lead product includes mdHACM, a micronized form of AMNIOFIX, supplied in powder form. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. is headquartered in Marietta, Georgia.
AI Analysis | Feedback
Here are 1-2 brief analogies for MiMedx (MDXG):
A specialized Johnson & Johnson, exclusively dedicated to developing advanced regenerative biomaterials for wound healing and surgical repair.
Think of Stryker, but specialized in regenerative biomaterials for complex wound healing and soft tissue repair, rather than orthopedic hardware.
AI Analysis | Feedback
```html- AmnioFix: A placental tissue allograft used in surgical applications and wound management to promote healing and reduce inflammation.
- EpiFix: A placental tissue allograft primarily utilized for the treatment of chronic and acute wounds, such as diabetic foot ulcers and venous leg ulcers.
- EpiBurn: A placental tissue allograft specifically indicated for the management and healing of burn wounds.
- AmnioCord: An umbilical cord allograft providing regenerative properties for various wound care applications.
AI Analysis | Feedback
MiMedx (MDXG) primarily sells its products to other companies and organizations within the healthcare industry, rather than directly to individuals.
The company's primary customers are various healthcare institutions. While MiMedx enters into contracts with Group Purchasing Organizations (GPOs) and works with third-party distributors to facilitate sales, its ultimate customers (the end-users of its products) are a diverse group of healthcare providers. Financial disclosures by MiMedx do not identify any single specific public company or private company as a major customer that accounts for a significant portion of its revenue, indicating a broad customer base. Therefore, specific names of major customer companies or their symbols cannot be provided.
MiMedx's products are sold to the following types of institutions:
- Hospitals
- Ambulatory Surgical Centers (ASCs)
- Physician Offices
- Wound Care Centers
- Long-term care facilities
AI Analysis | Feedback
null
AI Analysis | Feedback
Joseph H. Capper, Chief Executive Officer
Mr. Capper joined MiMedx in January 2023. He is an accomplished healthcare executive with nearly 30 years of experience in MedTech and Life Sciences leadership roles. Mr. Capper successfully led several organizations, most recently serving as CEO of BioTelemetry, which was acquired by Royal Philips for $2.8 billion. Prior to BioTelemetry, he served as President and CEO of both Home Diagnostics and CCS Medical, which were also acquired at substantial premiums. Earlier in his career, he held several leadership roles during a decade with Bayer AG and served as an officer in the U.S. Navy.
Doug Rice, Chief Financial Officer
Mr. Rice joined MiMedx in July 2023. He brings over a decade of experience in the MedTech industry, having served in various executive leadership positions. Most recently, he was the CFO of Orthofix Medical. Before Orthofix, Mr. Rice served as CFO at Vision Source and held several finance leadership roles at McAfee and Concentra. He began his career at PricewaterhouseCoopers and is a Certified Public Accountant.
Ricci Whitlow, Chief Operating Officer
Ms. Whitlow joined MiMedx in January 2023. She brings more than 30 years of Life Sciences and Pharmaceutical experience to her role. Prior to MiMedx, she served as President, Clinical Supply Services at Catalent Pharma Solutions. Her extensive career also includes leadership positions at Optinose, LifeCell, Kinetic Concepts, and Johnson & Johnson.
Kim Moller, Chief Commercial Officer
Ms. Moller joined MiMedx in August 2020 as Senior Vice President, Sales and was appointed Chief Commercial Officer in June 2024.
John Harper, Ph. D., Chief Technology Officer and Senior Vice President of Research and Product Development
Dr. Harper joined MiMedx in June 2021. Most recently, he served as a Senior Medical Scientist in the Medical Solutions Division of 3M Health Care and as Chief Technology Officer for 3M affiliate KCI. At KCI, he was responsible for all early-stage research, innovation, and technology development, as well as the study of the mechanism of action of the company's negative pressure wound care technology. He also led KCI's Clinical Development and Regulatory Affairs organization.
AI Analysis | Feedback
The key risks to MiMedx's business are primarily centered around regulatory changes, reimbursement policies, and a history of compliance challenges.
- Regulatory Changes, Reimbursement Policy Uncertainty, and Past/Present Legal & Compliance Issues: MiMedx faces significant risks due to evolving Medicare reimbursement policies, including the 2026 Physician Fee Schedule final rule and revised Local Coverage Determinations (LCDs) aimed at addressing fraud and abuse within the skin substitute industry. These changes could lead to increased scrutiny on the clinical effectiveness of its products and potential near-term price pressure. Historically, MiMedx has faced substantial financial difficulties and reputational damage due to allegations of mismanagement, fraud to inflate revenue, and issues with sales practices between 2016 and 2019, resulting in an SEC lawsuit and financial restatements. More recently, former employees have filed counterclaims alleging fraudulent practices, pressuring healthcare providers to use medically unnecessary products, and schemes to defraud Medicare. An FDA warning letter in December 2023 regarding the AXIOFILL product further highlights potential regulatory non-compliance. These ongoing legal and regulatory challenges pose risks of substantial financial penalties, damage to the company's reputation, and impacts on its ability to market products.
- Competition and the Need for Robust Clinical Evidence: Operating in the biotechnology sector, MiMedx is subject to intense competitive pressures. To maintain market position and secure favorable reimbursement, the company must continually demonstrate strong clinical evidence for its products, especially with increased regulatory emphasis on well-powered, peer-reviewed clinical data. The need to differentiate its products and ensure market acceptance against competing therapies is a constant challenge.
AI Analysis | Feedback
null
AI Analysis | Feedback
The addressable markets for MiMedx's main products and services are as follows:
- For the **U.S. Advanced Wound Care** market, the addressable market size is estimated at $0.9 billion. This market is addressed by products such as EPIFIX, EPICORD, EPIEFFECT, and CELERA.
- For the **U.S. Surgical Recovery** market, the addressable market size is estimated at $0.5 billion. MiMedx's products in this area include AMNIOFIX, AMNIOCORD, AMNIOBURN, AMNIOEFFECT, AXIOFILL, and HELIOGEN.
- In **Japan**, the addressable market MiMedx is targeting, particularly with products like EPIFIX, is estimated at $1.1 billion.
AI Analysis | Feedback
Here are the expected drivers of future revenue growth for MiMedx (MDXG) over the next 2-3 years:- Sustained Growth in Wound and Surgical Franchises: MiMedx has demonstrated consistent strong performance in both its Wound and Surgical divisions. The company's CEO, Joseph Capper, reported "strong top line growth in both our Wound and Surgical franchises" in Q3 2025. Specifically, wound product sales increased by 40% year-over-year, and surgical product sales grew by 26% in Q3 2025. This continued momentum across its core business segments is a key driver for future revenue.
- Launch and Expansion of New Products: The introduction and scaling of new products are expected to contribute significantly to revenue growth. MiMedx has highlighted the successful launch and progress of several new products, including EPIEFFECT, HELIOGEN, CELERA, EMERGE, and EPIXPRESS. The full market release of EPIXPRESS is underway with positive early feedback, and the company is seeing accelerated contributions from products like HELIOGEN in the surgical market. This expansion of the product portfolio provides multiple avenues for market share gains.
- Expansion of the Surgical Market Footprint: MiMedx is actively focusing on increasing its presence in the surgical market. The surgical business has shown significant growth, with a 26% year-over-year increase in Q3 2025. The company's strategy includes enhancing customer intimacy through initiatives like MiMedx Connect and continuing to develop innovative products specifically for the surgical market.
- Benefits from Medicare Reimbursement Reforms: While upcoming Medicare reimbursement reforms in 2026 may introduce some initial market choppiness, MiMedx's management anticipates these changes will ultimately bring stability and predictability to the industry. The company views these reforms as a "net positive" that could create opportunities as some competitors may exit the market due to the evolving policy landscape. MiMedx believes it is well-positioned to adapt and lead the market post-reform.
- Growth in International Business: MiMedx's international business has shown strong performance, with Q3 2024 marking the "highest level of international net sales" in many years. Continued expansion in international markets represents an additional driver for overall revenue growth.
AI Analysis | Feedback
Share Repurchases
- In October 2023, MiMedx repurchased $9.5 million of its Series B Convertible Preferred Stock.
- In 2022, the company repurchased common stock worth approximately $1.2 million, corresponding to 249,442 shares, to satisfy employee tax withholding obligations upon the vesting of restricted stock awards and the exercise of stock options.
- In 2021, MiMedx repurchased common stock totaling approximately $4.8 million, representing 469,239 shares, for employee tax withholding obligations related to equity awards.
Share Issuance
- MiMedx's common stock outstanding significantly increased from 113,705,447 shares at December 31, 2022, to 146,227,639 shares at December 31, 2023.
- This increase in shares outstanding in 2023 was primarily due to the conversion of all 95,000 outstanding shares of Series B Convertible Preferred Stock into common stock on December 22, 2023.
- The company's additional paid-in capital increased from $173.804 million at December 31, 2022, to $276.249 million at December 31, 2023, indicating significant equity-related transactions, including share issuances for compensation and the preferred stock conversion.
Inbound Investments
- MiMedx refinanced its existing indebtedness in January 2024 by obtaining new senior secured credit facilities totaling $95 million, comprised of a $75 million revolving credit facility and a $20 million term loan facility, to support future growth objectives.
Outbound Investments
- No significant outbound investments in other companies by MiMedx were identified within the last 3-5 years.
Capital Expenditures
- For the nine months ended September 30, 2025, capital expenditures, including purchases of equipment, totaled approximately $0.748 million.
- Capital expenditures, including purchases of equipment, were approximately $1.683 million for the full year 2024 and $1.987 million for the full year 2023.
- Capital expenditures are primarily focused on supporting the development and launch of new products and ongoing investments in the company's product pipeline, such as the randomized controlled trial for EPIEFFECT.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| MiMedx Earnings Notes | 12/16/2025 | |
| How Low Can MiMedx Stock Really Go? | 10/17/2025 | |
| MiMedx (MDXG) Debt Comparison | 08/08/2025 | |
| MiMedx (MDXG) Operating Cash Flow Comparison | 08/08/2025 | |
| MiMedx (MDXG) EBITDA Comparison | 08/08/2025 | |
| MiMedx (MDXG) Net Income Comparison | 08/08/2025 | |
| MiMedx (MDXG) Tax Expense Comparison | 08/08/2025 | |
| MiMedx (MDXG) Operating Income Comparison | 08/08/2025 | |
| MiMedx (MDXG) Revenue Comparison | 08/08/2025 | |
| Why MiMedx Stock Moved: MDXG Stock Has Gained 156% Since 2022 Fiscal End, Primarily Due To Favorable Change In Price To Sales Multiple (P/S) | 08/08/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to MDXG.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 01302026 | VEEV | Veeva Systems | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | -14.6% | -14.6% | -15.7% |
| 01162026 | BIIB | Biogen | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 19.5% | 19.5% | 0.0% |
| 01162026 | BMRN | BioMarin Pharmaceutical | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 9.7% | 9.7% | 0.0% |
| 01162026 | DOCS | Doximity | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -39.4% | -39.4% | -40.1% |
| 01022026 | CORT | Corcept Therapeutics | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | 4.6% | 4.6% | -9.1% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 11.99 |
| Mkt Cap | 0.9 |
| Rev LTM | 465 |
| Op Inc LTM | 31 |
| FCF LTM | 20 |
| FCF 3Y Avg | 41 |
| CFO LTM | 68 |
| CFO 3Y Avg | 46 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 11.2% |
| Rev Chg 3Y Avg | 10.8% |
| Rev Chg Q | 16.6% |
| QoQ Delta Rev Chg LTM | 3.9% |
| Op Mgn LTM | 2.7% |
| Op Mgn 3Y Avg | 4.3% |
| QoQ Delta Op Mgn LTM | 1.8% |
| CFO/Rev LTM | 17.2% |
| CFO/Rev 3Y Avg | 12.5% |
| FCF/Rev LTM | 7.9% |
| FCF/Rev 3Y Avg | 2.9% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 0.9 |
| P/S | 2.0 |
| P/EBIT | 28.2 |
| P/E | 44.5 |
| P/CFO | 11.4 |
| Total Yield | 0.7% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 1.3% |
| D/E | 0.1 |
| Net D/E | -0.0 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 0.0% |
| 3M Rtn | -4.0% |
| 6M Rtn | -15.9% |
| 12M Rtn | -34.7% |
| 3Y Rtn | 25.5% |
| 1M Excs Rtn | 0.9% |
| 3M Excs Rtn | -8.3% |
| 6M Excs Rtn | -21.4% |
| 12M Excs Rtn | -47.0% |
| 3Y Excs Rtn | -38.6% |
Price Behavior
Price Behavior
| Market Price | $5.22 | |
| Market Cap ($ Bil) | 0.8 | |
| First Trading Date | 06/24/2008 | |
| Distance from 52W High | -37.9% | |
| 50 Days | 200 Days | |
| DMA Price | $6.04 | $6.65 |
| DMA Trend | down | down |
| Distance from DMA | -13.6% | -21.5% |
| 3M | 1YR | |
| Volatility | 33.1% | 40.1% |
| Downside Capture | 186.07 | 125.89 |
| Upside Capture | 28.60 | 63.08 |
| Correlation (SPY) | 22.8% | 35.0% |
MDXG Betas & Captures as of 1/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.21 | 0.43 | 0.97 | 1.09 | 0.72 | 0.81 |
| Up Beta | 1.12 | 0.06 | 1.65 | 1.21 | 0.57 | 0.77 |
| Down Beta | -0.96 | -0.44 | -0.25 | 0.76 | 0.72 | 0.86 |
| Up Capture | -203% | -49% | -0% | 48% | 38% | 56% |
| Bmk +ve Days | 11 | 22 | 34 | 71 | 142 | 430 |
| Stock +ve Days | 5 | 15 | 23 | 51 | 106 | 356 |
| Down Capture | 430% | 255% | 229% | 174% | 114% | 97% |
| Bmk -ve Days | 9 | 19 | 27 | 54 | 109 | 321 |
| Stock -ve Days | 15 | 25 | 36 | 70 | 137 | 376 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with MDXG | |
|---|---|---|---|---|
| MDXG | -40.4% | 39.9% | -1.21 | - |
| Sector ETF (XLV) | 10.4% | 17.3% | 0.41 | 31.6% |
| Equity (SPY) | 13.6% | 19.4% | 0.53 | 35.8% |
| Gold (GLD) | 73.5% | 25.5% | 2.13 | 0.4% |
| Commodities (DBC) | 7.9% | 17.0% | 0.28 | 2.2% |
| Real Estate (VNQ) | 7.1% | 16.7% | 0.24 | 24.8% |
| Bitcoin (BTCUSD) | -31.1% | 44.9% | -0.69 | 19.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with MDXG | |
|---|---|---|---|---|
| MDXG | -13.3% | 63.2% | 0.07 | - |
| Sector ETF (XLV) | 7.9% | 14.5% | 0.36 | 26.7% |
| Equity (SPY) | 13.5% | 17.0% | 0.63 | 34.2% |
| Gold (GLD) | 21.7% | 17.1% | 1.04 | 1.9% |
| Commodities (DBC) | 10.8% | 19.0% | 0.45 | 2.5% |
| Real Estate (VNQ) | 4.9% | 18.8% | 0.17 | 28.3% |
| Bitcoin (BTCUSD) | 8.4% | 57.2% | 0.37 | 12.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with MDXG | |
|---|---|---|---|---|
| MDXG | -10.7% | 67.4% | 0.13 | - |
| Sector ETF (XLV) | 11.3% | 16.5% | 0.57 | 24.7% |
| Equity (SPY) | 15.9% | 17.9% | 0.76 | 28.8% |
| Gold (GLD) | 15.0% | 15.6% | 0.80 | 2.0% |
| Commodities (DBC) | 8.6% | 17.6% | 0.40 | 7.4% |
| Real Estate (VNQ) | 6.9% | 20.7% | 0.30 | 24.3% |
| Bitcoin (BTCUSD) | 68.0% | 66.7% | 1.07 | 7.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 10/29/2025 | 2.9% | 10.7% | -7.2% |
| 7/30/2025 | 10.3% | 11.0% | 10.1% |
| 2/26/2025 | 1.6% | 0.9% | -3.4% |
| 10/30/2024 | 20.4% | 31.8% | 62.6% |
| 7/31/2024 | -10.3% | -15.8% | -10.2% |
| 2/28/2024 | -0.5% | -1.6% | -6.1% |
| 10/30/2023 | 3.8% | 5.9% | 23.1% |
| 8/1/2023 | -2.9% | -7.6% | -7.2% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 10 | 10 | 7 |
| # Negative | 7 | 7 | 10 |
| Median Positive | 4.6% | 8.3% | 20.5% |
| Median Negative | -4.9% | -6.2% | -5.1% |
| Max Positive | 20.4% | 31.8% | 62.6% |
| Max Negative | -13.0% | -15.8% | -29.1% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 10/29/2025 | 10-Q |
| 06/30/2025 | 07/30/2025 | 10-Q |
| 03/31/2025 | 04/30/2025 | 10-Q |
| 12/31/2024 | 02/26/2025 | 10-K |
| 09/30/2024 | 10/30/2024 | 10-Q |
| 06/30/2024 | 07/31/2024 | 10-Q |
| 03/31/2024 | 04/30/2024 | 10-Q |
| 12/31/2023 | 02/28/2024 | 10-K |
| 09/30/2023 | 10/30/2023 | 10-Q |
| 06/30/2023 | 08/01/2023 | 10-Q |
| 03/31/2023 | 05/02/2023 | 10-Q |
| 12/31/2022 | 02/28/2023 | 10-K |
| 09/30/2022 | 11/02/2022 | 10-Q |
| 06/30/2022 | 08/02/2022 | 10-Q |
| 03/31/2022 | 05/03/2022 | 10-Q |
| 12/31/2021 | 02/28/2022 | 10-K |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Maersk-Moller, Kimberly | Chief Commercial Officer | Direct | Sell | 11102025 | 7.42 | 58,300 | 432,329 | 1,757,364 | Form |
| 2 | Capper, Joseph H | Chief Executive Officer | Direct | Buy | 5052025 | 6.34 | 200,000 | 1,268,000 | 3,357,220 | Form |
| 3 | Maersk-Moller, Kimberly | Chief Commercial Officer | Direct | Sell | 3192025 | 8.04 | 1,759 | 14,142 | 2,484,979 | Form |
| 4 | Hulse, William Frank Iv | General Counsel and CAO | Direct | Sell | 3142025 | 7.89 | 54,596 | 430,762 | 3,473,004 | Form |
| 5 | Maersk-Moller, Kimberly | Chief Commercial Officer | Direct | Sell | 3142025 | 7.89 | 4,106 | 32,396 | 2,452,496 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.